Clinical trials: Prostate
Prostate Cancer, Urological Cancer
Evaluation of the PI-RADS v2.1 Score Using Multiple Readers
The interpretation of prostate multiparametric MRI (mpMRI) is difficult and requires expertise. As a result, it suffers from substantial inter-reader variability.
- Trial name
- MULTI (NCT04299997)
- Testing
- Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer, Prostate Adenocarcinoma
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Disease
- Trial name
- NCT03503643
- Testing
- Hemigland Cryoablation
- Where
- United States
- Volunteers
- 354 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Ultrasound Score, Transurethral Resection (TUR) Syndrome
Lung Ultrasound Versus Inferior Vena Cava Collapsibility Index for Early Prediction of Volume Overload During Transurethral Resection of Prostate
The aim of this study is to compare between accuracy of lung US and IVC CI for early prediction of volume overload during TURP. Primary outcome: The incidence of volume overload during transurethral resection of prostate.
- Conditions
- Lung Ultrasound Score, Transurethral Resection (TUR) Syndrome, Prostate
- Trial name
- NCT07164638
- Testing
- lung ultrasound (LUS), IVC collapsibility index
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Prostate Cancer
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy).
- Trial name
- VAPOR-LTR (NCT07455058)
- Testing
- Vanquish Therapy
- Where
- 4 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Francis Medical Inc.
Hormone Refractory Prostate Cancer
Radiotherapy vs Observation for CRPC
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
- Trial name
- NCT01590498
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhengzhou University
Prostate Cancer
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage IV…
- Trial name
- NCT00004149
- Testing
- arsenic trioxide
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Albert Einstein College of Medicine
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer.
- Trial name
- NCT01543776
- Testing
- abiraterone acetate
- Where
- 6 sites in United States, Singapore
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Breast Cancer, Cervical Cancer
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Breast Cancer, Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00601406
- Testing
- gene expression analysis, gene rearrangement analysis, polymorphism analysis
- Where
- 11 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- The Christie NHS Foundation Trust
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Leukemia, Myeloid, Neoplasm Metastasis
Analyses of Human Samples Collected in Clinical Trials
Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes.
- Conditions
- Leukemia, Myeloid, Neoplasm Metastasis, Leukemia, Lymphoid, Prostate Cancer
- Trial name
- NCT00339664
- Where
- 17 sites in United States, Netherlands
- Volunteers
- 2,579 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated machine vision based image analysis of…
- Trial name
- NCT00578409
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms, Lymphatic Metastasis
Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in Prostate Cancer
The goal of this diagnostic test is to prospectively test the performance of pre-developed artificial intelligence (AI) diagnostic model for detecting pathological lymph node metastasis (LNM) of prostate cancer.
- Trial name
- NCT06253065
- Testing
- Artificial intelligence (AI)-based diagnostic model (developed)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men
Men with early prostate cancer face a number of options which lie at the extremes of care. On one hand, active surveillance involves monitoring the disease and on the other, immediate treatment involves surgery or radiotherapy.
- Trial name
- MAGNABLATE I (NCT02033447)
- Testing
- Magnetic Nanoparticle Injection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College London Hospitals
Prostate Cancer Metastatic
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
This is a Long Term Follow Up study to eRADicAte, an open label study designed to examine the effects of Radium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone Castrate-Resistant…
- Trial name
- Post-eRADicAte (NCT03414437)
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Carolina Research Professionals, LLC
Prostate Cancer, Diffusion MRI
MR Microstructural Imaging for Prostate Cancer Diagnosis
The goal of this multi-center clinical study is to evaluate whether time-dependent diffusion MRI (TDDMRI) can provide reliable microstructural imaging markers for the diagnosis of prostate cancer.
- Trial name
- NCT07249281
- Testing
- MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Benign Prostatic Hyperplasia
Thulium Laser Versus Bipolar Enucleation of the Prostate
Comparing the peri-operative outcomes in patients with benign prostatic hyperplasia (BPH) who will undergo bipolar enucleation of the prostate versus thulium laser enucleation.
- Trial name
- NCT05200065
- Testing
- Thulium laser enucleation of the prostate, Bipolar enucleation of the prostate
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
Prostate Cancer
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
- Trial name
- NCT03209492
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 333 people
- Sponsor
- Takeda
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer